These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38741588)

  • 1. Editorial: Recent advances in cardiotoxicity testing, volume II.
    Salama AM; Mohamed TMA
    Front Pharmacol; 2024; 15():1414373. PubMed ID: 38741588
    [No Abstract]   [Full Text] [Related]  

  • 2. Protein-encapsulated doxorubicin reduces cardiotoxicity in hiPSC-cardiomyocytes and cardiac spheroids while maintaining anticancer efficacy.
    Arzt M; Gao B; Mozneb M; Pohlman S; Cejas RB; Liu Q; Huang F; Yu C; Zhang Y; Fan X; Jenkins A; Giuliano AE; Burridge PW; Cui X; Sharma A
    Stem Cell Reports; 2023 Oct; 18(10):1913-1924. PubMed ID: 37657447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Merits of hiPSC-Derived Cardiomyocytes for In Vitro Research and Testing Drug Toxicity.
    Wang PH; Fang YH; Liu YW; Yeh ML
    Biomedicines; 2022 Oct; 10(11):. PubMed ID: 36359284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers.
    Monteiro da Rocha A; Allan A; Block T; Creech J; Herron TJ
    J Vis Exp; 2023 Mar; (193):. PubMed ID: 37036202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Action potential metrics and automated data analysis pipeline for cardiotoxicity testing using optically mapped hiPSC-derived 3D cardiac microtissues.
    Soepriatna AH; Navarrete-Welton A; Kim TY; Daley MC; Bronk P; Kofron CM; Mende U; Coulombe KLK; Choi BR
    PLoS One; 2023; 18(2):e0280406. PubMed ID: 36745602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.
    Sharma A; Burridge PW; McKeithan WL; Serrano R; Shukla P; Sayed N; Churko JM; Kitani T; Wu H; Holmström A; Matsa E; Zhang Y; Kumar A; Fan AC; Del Álamo JC; Wu SM; Moslehi JJ; Mercola M; Wu JC
    Sci Transl Med; 2017 Feb; 9(377):. PubMed ID: 28202772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proposal for considerations during human iPSC-derived cardiac organoid generation for cardiotoxicity drug testing.
    Lee SW; Song M; Woo DH; Jeong GS
    Biomed Pharmacother; 2024 May; 174():116511. PubMed ID: 38574616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.
    Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y
    Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Extracellular-Matrix Functionalization of 3D hiPSC-Based Cardiac Tissues Improves Cardiomyocyte Maturation.
    Almeida HV; Tenreiro MF; Louro AF; Abecasis B; Santinha D; Calmeiro T; Fortunato E; Ferreira L; Alves PM; Serra M
    ACS Appl Bio Mater; 2021 Feb; 4(2):1888-1899. PubMed ID: 35014458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.
    Zwartsen A; de Korte T; Nacken P; de Lange DW; Westerink RHS; Hondebrink L
    J Mol Cell Cardiol; 2019 Nov; 136():102-112. PubMed ID: 31526813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanobiology Assays with Applications in Cardiomyocyte Biology and Cardiotoxicity.
    Blair CA; Pruitt BL
    Adv Healthc Mater; 2020 Apr; 9(8):e1901656. PubMed ID: 32270928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functionally Integrated Top-Down Proteomics for Standardized Assessment of Human Induced Pluripotent Stem Cell-Derived Engineered Cardiac Tissues.
    Melby JA; de Lange WJ; Zhang J; Roberts DS; Mitchell SD; Tucholski T; Kim G; Kyrvasilis A; McIlwain SJ; Kamp TJ; Ralphe JC; Ge Y
    J Proteome Res; 2021 Feb; 20(2):1424-1433. PubMed ID: 33395532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating nonlinear analysis and machine learning for human induced pluripotent stem cell-based drug cardiotoxicity testing.
    Kowalczewski A; Sakolish C; Hoang P; Liu X; Jacquir S; Rusyn I; Ma Z
    J Tissue Eng Regen Med; 2022 Aug; 16(8):732-743. PubMed ID: 35621199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).
    Narkar A; Willard JM; Blinova K
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthracycline-Induced Cardiotoxicity: Molecular Insights Obtained from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).
    Bozza WP; Takeda K; Alterovitz WL; Chou CK; Shen RF; Zhang B
    AAPS J; 2021 Mar; 23(2):44. PubMed ID: 33719006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase IIα to IIβ in human stem cell derived cardiomyocytes.
    Cui N; Wu F; Lu WJ; Bai R; Ke B; Liu T; Li L; Lan F; Cui M
    J Cell Mol Med; 2019 Jul; 23(7):4627-4639. PubMed ID: 31106979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-lineage heart-chip models drug cardiotoxicity and enhances maturation of human stem cell-derived cardiovascular cells.
    Mozneb M; Jenkins A; Sances S; Pohlman S; Workman MJ; West D; Ondatje B; El-Ghazawi K; Woodbury A; Garcia VJ; Patel S; Arzt M; Dezem F; Laperle AH; Moser VA; Ho R; Yucer N; Plummer J; Barrett RJ; Svendsen CN; Sharma A
    Lab Chip; 2024 Feb; 24(4):869-881. PubMed ID: 38252454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering hiPSC cardiomyocyte in vitro model systems for functional and structural assessment.
    Schroer A; Pardon G; Castillo E; Blair C; Pruitt B
    Prog Biophys Mol Biol; 2019 Jul; 144():3-15. PubMed ID: 30579630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
    Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
    Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induced Pluripotent Stem Cell-Derived Cardiomyocytes: A Platform for Testing For Drug Cardiotoxicity.
    Bernstein D
    Prog Pediatr Cardiol; 2017 Sep; 46():2-6. PubMed ID: 29200805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.